免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting DNMT1 augments anti-tumor CD8⁺ T cell function.
Targeting DNMT1 augments anti-tumor CD8⁺ T cell function.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境(TME)中CD8⁺ T细胞的慢性刺激诱导一种功能低下状态,其特征为细胞毒性减弱和抗肿瘤功能受损,即耗竭。耗竭与表观遗传改变相关,这些改变即使在接受免疫检查点抑制(ICI)等干预后仍相对稳定。尽管表观遗传改变具有潜在可逆性,但有效恢复耗竭CD8⁺ T细胞功能的治疗策略报道仍然有限。
在此,我们报道DNA甲基转移酶1(DNMT1)抑制(DNMT1i)在抗肿瘤反应中对抗CD8⁺ T细胞功能障碍。我们显示,DNMT1i与ICI协同作用,在黑色素瘤模型中挽救慢性刺激CD8⁺ T细胞的肿瘤细胞杀伤活性。DNMT1i减轻耗竭的转录特征,同时诱导一种不同的效应程序。DNMT1i减弱与耗竭相关的染色质可及性整体增加,并在再刺激后实现耗竭染色质景观的表观遗传重塑。
最后,DNMT1i增强黑色素瘤患者来源的TIL(肿瘤浸润淋巴细胞)在长期体外扩增后的效应功能。这些研究确立靶向DNMT1作为对抗CD8⁺ T细胞耗竭并增强ICI疗效的一种有前景的策略。
Chronic stimulation of CD8⁺ T cells within the tumor microenvironment (TME) induces a hypofunctional state characterized by diminished cytotoxicity and functionally impaired anti-tumor function, known as exhaustion. Exhaustion is associated with epigenetic changes that remain relatively stable despite interventions like immune checkpoint inhibition (ICI). Although epigenetic changes are potentially reversible, reports of therapeutic strategies to effectively restore function in exhausted CD8⁺ T cells remain limited.
Here, we report DNA methyltransferase 1 (DNMT1) inhibition (DNMT1i) in counteracting CD8 + T cell dysfunction during the anti-tumor response.
We show that DNMT1i synergizes with ICI to rescue the tumor cell killing activity of chronically stimulated CD8⁺ T cells in a melanoma model. DNMT1i mitigates transcriptional features of exhaustion while inducing a divergent effector program. DNMT1i attenuates the global increase in chromatin accessibility associated with exhaustion and enables epigenetic remodeling of the exhausted chromatin landscape upon restimulation.
Finally, DNMT1i enhances the effector function of melanoma patient-derived tumor infiltrating lymphocytes after prolonged ex vivo expansion. These studies establish DNMT1 targeting as a promising strategy to counteract CD8⁺ T cell exhaustion and potentiate ICI efficacy.
MEMBER ACCOUNT
登录成功会直接打开下一页。